CERS - Cerus Corporation logo

Cerus Corporation

CERS

Cerus Corporation develops and commercializes the INTERCEPT Blood System, a technology designed to inactivate blood-borne pathogens in donated blood components, including platelets, plasma, and red blood cells, enhancing blood safety for transfusions.

โš•๏ธ Healthcare NASDAQ Listed 1997 $ USD
$1,000 invested 20 years ago โ†’$445today

Score Overview

1 Year
Score
Net Growth56.59%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth10.50%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score7.8
Net Growth87.53%
Net TrendEvery year
Net Income Consistencyโ€”
Rev Growth74.07%
Rev Trend80%
Revenue Consistencyโ€”
10 Years
Score
Net Growth89.22%
Net Trend90%
Net Income Consistency
Rev Growth6x
Rev Trend90%
Revenue Consistency
20 Years
Score4.7
Net Growth-41.93%
Net Trend70%
Net Income Consistency
Rev Growth6x
Rev Trend80%
Revenue Consistency
All Time
Score
Net Growth53.86%
Net Trend59%
Net Income Consistency
Rev Growth33x
Rev Trend76%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Cerus Corporation has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • CERS

2008: 96.6% ยท 2021: 70.6% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-29
$ 2.47โ€”
1 Year2025-09-29
$ 1.5262.50%
5 Years2021-09-29
$ 6.09-59.44%
10 Years2016-09-29
$ 6.12-59.64%
20 Years2006-09-29
$ 5.55-55.50%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 227M-$ 6M$ 56M
2025$ 206M-$ 15M$ 82M
2024$ 180M-$ 20M$ 80M
2023$ 156M-$ 37M$ 65M
2022$ 162M-$ 42M$ 102M
2021$ 130M-$ 54M$ 129M
2020$ 91M-$ 59M$ 133M
2019$ 74M-$ 71M$ 85M
2018$ 60M-$ 57M$ 117M
2017$ 43M-$ 60M$ 60M
2016$ 37M-$ 62M$ 71M
2015$ 34M-$ 55M$ 107M
2014$ 36M-$ 38M$ 51M
2013$ 39M-$ 43M$ 57M
2012$ 36M-$ 15M$ 26M
2011$ 33M-$ 16M$ 25M
2010$ 23M-$ 16M$ 30M
2009$ 17M-$ 24M$ 19M
2008$ 16M-$ 29M$ 22M
2007$ 11M-$ 45M$ 56M
2006$ 35M-$ 4M$ 93M
2005$ 24M$ 13M$ 45M
2004$ 13M-$ 31M$ 95M
2003$ 9M-$ 58M$ 110M
2002$ 8M-$ 57M$ 64M
2001$ 4M-$ 49M$ 123M
2000$ 1M-$ 36M$ 90M
1999$ 2M-$ 22M$ 40M
1998$ 2M-$ 29M$ 6M
IPO1997$ 6M-$ 14M$ 11M
CERS - Cerus Corporation logo

Cerus Corporation fundamental performance

Between 2020 and 2025, revenue grew from $ 91M to $ 206M and net income went from -$ 59M to -$ 15M. Revenue increased in 4 of those 5 years; net income in every one.

Between 2015 and 2025, revenue grew from $ 34M to $ 206M and net income went from -$ 55M to -$ 15M. Revenue increased in 9 of those 10 years; net income in 9.

Cerus Corporation currently holds a 20-year HDB Score of 4.7 out of 10. How the HDB Score is calculated.

Membership

Continue CERSโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies